Status:
UNKNOWN
FoxO3a and PU.1 in Acute Lymphoblastic Leukemia
Lead Sponsor:
Assiut University
Conditions:
Acute Lymphoblastic Leukemia
Eligibility:
All Genders
2-17 years
Brief Summary
Acute Lymphoblastic Leukemia (ALL) is one of the four major types of leukemia which is common in both children and adolescents; however, it is the most common pediatric malignancy diagnosed in childre...
Detailed Description
Proto-oncogenes and tumor suppressor genes are the most important genes involved in leukemogenesis , which their alterations disrupt normal regulatory processes such as self-renewal, proliferation, di...
Eligibility Criteria
Inclusion
- children aged 2-17 years and diagnosed as new cases of acute lymphoblastic leukemia
Exclusion
- age more than 17 years
- presence of other hematological disorders, history of other malignancies ,or relapsed ALL
- patients under chemotherapy or radiotherapy
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT04092348
Start Date
August 1 2023
End Date
December 30 2024
Last Update
February 8 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.